This case study highlights a real-world example of artificial intelligence’s (AI) impact on medication adherence for a leading manufacturer’s major depressive disorder medication (MDD).
Overcoming Barriers to Medication Adherence
Around 50 percent of patients are non-adherent to their MDD. Others never make the first fill. A leading pharmaceutical company knew they needed an effective, efficient way to improve adherence, and they needed it fast.
Deepening Patient Engagement with AI
Recognizing the potential benefits of AI-powered patient engagement, the pharmaceutical company turned to AllazoHealth to kickstart an AI-enabled patient support program.
Increased Length of Therapy
Using AllazoHealth’s AI, the manufacturer increased its patients’ length of therapy by 13.3% (evaluated 180 days after program sign up). Additionally, the AI increased first fill rates by 8.4% for patients who received a co-pay card for the first-fill (evaluated 180 days after program sign up).
Download this free case study to learn about the benefits of AI-driven patient support in transforming engagement, adherence, and length of therapy. Fill out the form to get immediate access.